Virus infection inhibitor, resin composition, and virus infection inhibitor product

Abstract

The present invention provides a viral infection inhibitory agent that allows production of viral infection inhibitory products, such as films and coatings, for which a reduction in transparency is generally prevented even when the products are placed in a high-temperature environment. The viral infection inhibitory agent according to the present invention comprises a viral infection inhibitory compound having a sulfo group salt, and an organic acid in which the sum of Sanderson electronegativity, standardized for carbon, is 28 or less and in which the sum of first ionization tendency, standardized for carbon, is 30 or less. As a result of this configuration of the viral infection inhibitory agent, a viral infection inhibitory product that contains the viral infection inhibitory agent shows little reduction in transparency even when the product is placed in a high-temperature environment and thus exhibits an excellent appearance over a long period of time.

Description

[Technical Field]

[0001] The present invention relates to a virus infection inhibitor, a resin composition, and a virus infection inhibitor product. [Background technology]

[0002] In recent years, in addition to seasonal influenza virus epidemics, the novel coronavirus (COVID-19) has become a global pandemic.

[0003] Furthermore, highly pathogenic avian influenza viruses have mutated and been confirmed to infect humans, and there are also concerns about the SARS virus, which has an extremely high mortality rate, so anxiety about viruses is only increasing.

[0004] In response to these problems, Patent Document 1 proposes an antiviral surface treatment agent comprising a paint containing an antiviral agent, which is calcium carbonate supported by a sulfonic acid surfactant, and the paint is an ultraviolet-curable paint or an electron beam-curable paint. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Laid-Open No. 2016-128395 Summary of the Invention [Problem to be solved by the invention]

[0006] However, coating films and films containing the above-mentioned antiviral surface treatment agents have a problem in that their transparency decreases when placed in a high-temperature environment.

[0007] The present invention provides a virus infection inhibitor that can be used to form virus infection-preventing products such as coatings and films that are largely prevented from losing transparency even when placed in a high-temperature environment, or that can be mixed with a synthetic resin to form a resin composition that can be used to produce virus infection-preventing products, etc. [Means for solving the problem]

[0008] The viral infection inhibitor of the present invention comprises: a viral infection-inhibiting compound having a salt of a sulfo group; and an organic acid having a carbon-normalized sum of Sanderson electronegativities of 28 or less and a carbon-normalized sum of first ionization tendencies of 30 or less.

[0009] The resin composition of the present invention is characterized by containing a synthetic resin and the above-mentioned virus infection inhibitor.

[0010] The viral infection-preventing product of the present invention comprises a substrate and the viral infection-preventing agent contained in the substrate. [Effects of the Invention]

[0011] According to the virus infection inhibitor of the present invention, a virus infection inhibitor product containing this virus infection inhibitor exhibits almost no loss in transparency even when placed in a high-temperature environment, and maintains an excellent appearance for a long period of time (heat aging resistance).

[0012] The virus infection inhibitor of the present invention has excellent heat aging resistance, and therefore can impart a virus infection inhibitory effect to a substrate while maintaining the appearance of the substrate, without impairing the color or other appearance of the substrate. DETAILED DESCRIPTION OF THE INVENTION

[0013] The viral infection inhibitor of the present invention comprises: a viral infection-inhibiting compound having a salt of a sulfo group; and an organic acid having a sum of Sanderson electronegativities of 28 or less and a sum of first ionization tendencies of 30 or less.

[0014] [Viral infection inhibitor compound] The viral infection inhibitor of the present invention contains a viral infection inhibitory compound as an active ingredient. The viral infection inhibitory compound has a salt of a sulfo group (-SO3H) in the molecule.

[0015] The viral infection-inhibiting compound exerts a viral infection-inhibiting effect due to the salt of a sulfo group (-SO3H). The viral infection-inhibiting compound has an excellent viral infection-inhibiting effect, particularly against both enveloped and non-enveloped viruses.

[0016] The term "viral infection inhibitory effect" refers to the effect of eliminating or reducing the infectivity of viruses to cells, or preventing them from replicating within the cells even if they infect. Examples of methods for determining whether or not a virus is infective include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for plastics and non-porous surface products other than textiles. The Society of International Studies on Antimicrobial Articles (SIAA) certifies products that meet the safety and antiviral efficacy standards for antiviral finishing agents with an antiviral finish mark. The standard for antiviral efficacy is a difference (antiviral activity value) of 2.0 or more between the common logarithm of the viral infectivity titer of a blank product (product without antiviral finishing agent) and the common logarithm of the viral infectivity titer of a processed product (product with antiviral finishing agent added) in the ISO 21702 evaluation. Viral infection inhibitors are added to surface coating agents such as paints and are evaluated using the above evaluation method.

[0017] In the present invention, for example, when the viral infection inhibiting effect is evaluated under the following conditions, a coating film is deemed to have a viral infection inhibiting effect if the difference in the common logarithm of the viral infectivity (antiviral activity value) between the blank coating film and the test coating film is 2 or more. In this case, regardless of the type of virus being evaluated, a coating film is deemed to have a viral infection inhibiting effect if the difference in the common logarithm of the viral infectivity (antiviral activity value) between the blank coating film and the test coating film is 2.0 or more for at least one type of virus.

[0018] For example, the antiviral activity value can be measured as follows: 5 parts by mass of the virus infection inhibitor and 95 parts by mass of an ultraviolet-curable acrylic paint (manufactured by Coattec Co., Ltd., product name "AI-N2") were mixed to prepare a coating composition. The coating composition was applied to a polyethylene film using a wire bar coater #8 to form a coating layer with a thickness of 18 μm.

[0019] Using a UV conveyor, the coating layer was irradiated with ultraviolet light of 365 nm wavelength at an integrated light intensity of 500 mJ / cm at 25°C. 2 The UV-curable acrylic paint is cured by irradiating it so that a coating film with a thickness of 18 μm is formed. A test piece is prepared by cutting out a flat square piece with each side measuring 5.0 cm from the coating film.

[0020] The surface of the coating film on the obtained test piece is soaked in 1 mL of water with a flat square nonwoven fabric with sides of 10 cm (for example, a nonwoven fabric commercially available from Nippon Paper Crecia Co., Ltd. under the trade name "Kimwipe S-200"), and the coating film surface is wiped with the nonwoven fabric by moving it back and forth 10 times to obtain a test coating film.

[0021] The obtained test coating film is subjected to an antiviral test in accordance with ISO 21702. After the reaction, the virus suspension is subjected to the plaque method to calculate the virus infectivity of the test coating film.

[0022] A blank coating was prepared in the same manner as above, except that no virus infection inhibitor was added, and the virus infectivity (common logarithm) (PFU / cm) was calculated based on this blank coating in the same manner as above. 2 ) is calculated.

[0023] The antiviral activity value is calculated by subtracting the viral infectivity of the test coating from the viral infectivity of the blank coating.

[0024] Other methods include the plaque method and hemagglutination assay (HAU) as described in "Medical and Pharmaceutical Virology" (first published in April 1990).

[0025] The antiviral activity value of the viral infection inhibitor is more preferably 2.0 or higher, and even more preferably 3.0 or higher.

[0026] The salt of the sulfo group (-SO3H) is not particularly limited, and examples thereof include sodium salt (-SO3Na), calcium salt [(-SO3 - )2Ca 2+ ], ammonium salt (-SO3 - NH4 + ), magnesium salt [(-SO3 - )2Mg 2+ ], barium salts [(-SO3 - )2Ba 2+ and the like, and sodium salts are preferred.

[0027] The viral infection-inhibiting compound containing a salt of a sulfo group may have one or more salts of a sulfo group in the molecule, and examples thereof include linear alkylbenzenesulfonates, α-olefinsulfonates, alkylphenyl ether sulfonates, alkyldiphenyl ether sulfonates, polyoxyalkylene alkyl ether sulfate ester salts, lauryl sulfate, polymers having a salt of a sulfo group in the side chain of a linear polymer, salts of polystyrenesulfonic acid, salts of formamidinesulfinic acid, salts of 3-aminobenzenesulfonic acid, salts of hydroxybenzenesulfonic acid, salts of m-xylene-4-sulfonic acid, salts of 5-sulfosalicylic acid, salts of sulfanilic acid, salts of 2-amino-3,5-dimethylbenzenesulfonic acid, salts of 1,3-phenylenediamine-4-sulfonic acid, salts of sulfonated (styrene-divinylbenzene copolymer), salts of carrageenan, salts of sulfonated polyethersulfone, and salts of ligninsulfonic acid.

[0028] Examples of linear alkylbenzenesulfonates include sodium dodecylbenzenesulfonate, calcium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, magnesium dodecylbenzenesulfonate, barium dodecylbenzenesulfonate, sodium tridecylbenzenesulfonate, ammonium tridecylbenzenesulfonate, sodium tetradecylbenzenesulfonate, and ammonium tetradecylbenzenesulfonate, with sodium dodecylbenzenesulfonate being preferred.

[0029] Examples of α-olefin sulfonates include C12 to C18 sodium olefin sulfonate, C12 to C18 calcium olefin sulfonate, C12 to C18 ammonium olefin sulfonate, C12 to C18 magnesium olefin sulfonate, and C12 to C18 barium olefin sulfonate, with C14 sodium tetradecene sulfonate being preferred.

[0030] Examples of alkyl diphenyl ether sulfonates include sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkyl diphenyl ether sulfonic acids in which the alkyl group is C6 to C18.

[0031] Examples of alkyl phenyl ether sulfonates include sodium salts, calcium salts, ammonium salts, magnesium salts, and barium salts of alkyl phenyl ether sulfonic acids in which the alkyl group is C6 to C18.

[0032] In the present invention, an alkyl group is a monovalent atomic group remaining after removing one hydrogen atom from an aliphatic saturated hydrocarbon.

[0033] In the polymer having a salt of a sulfo group in the side chain of a linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymers, polyesters, and polyurethanes are preferred, with vinyl polymers being more preferred.

[0034] The polymer having a salt of a sulfo group in the side chain of a linear polymer is not particularly limited, and examples thereof include a polymer containing a sulfo salt-containing monomer containing a salt of a sulfo group as a monomer unit.

[0035] Examples of polymers containing, as monomer units, sulfo group salt-containing monomers containing a salt of a sulfo group include polymers containing styrene sulfonate units, styrene sulfonate homopolymers, styrene-styrene sulfonate copolymers, sulfonates of compounds obtained by sulfonating the benzene rings of polystyrene, and sulfonates of compounds obtained by sulfonating the benzene rings of polymers containing a styrene component.

[0036] The salt-containing monomer of a sulfo group is not particularly limited, and examples include sodium p-styrenesulfonate, sodium m-styrenesulfonate, sodium o-styrenesulfonate, calcium p-styrenesulfonate, calcium m-styrenesulfonate, calcium o-styrenesulfonate, ammonium p-styrenesulfonate, ammonium m-styrenesulfonate, and ammonium o-styrenesulfonate. Sodium styrenesulfonate is preferred, and sodium p-styrenesulfonate is more preferred due to its less steric hindrance in reactivity with viruses.

[0037] When the viral infection-inhibiting compound is a polymer, it may be a homopolymer of a sulfo group salt-containing monomer, or a copolymer of a sulfo group salt-containing monomer and a monomer copolymerizable with the sulfo group salt-containing monomer.

[0038] The monomer copolymerizable with the sulfo group salt-containing monomer is not particularly limited and includes, for example, alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, etc. The monomer copolymerizable with the infection-blocking functional group-containing monomer may be used alone or in combination of two or more.

[0039] The polymer that becomes the viral infection-inhibiting compound can be polymerized using a general-purpose polymerization method. For example, the viral infection-inhibiting compound can be obtained by polymerizing a monomer composition containing a sulfo group salt-containing monomer in the presence of a general-purpose radical polymerization initiator. Examples of the radical polymerization initiator include thermal cleavage radical polymerization initiators such as 1-hydroxycyclohexane-1-yl phenyl ketone, t-hexyl peroxypivalate, benzoyl peroxide, and azobisisobutyronitrile.

[0040] When the viral infection inhibiting compound contains a polymer, the weight-average molecular weight of the polymer is preferably 1,000 or more, more preferably 5,000 or more, more preferably 10,000 or more, and even more preferably 100,000 or more. When the weight-average molecular weight of the viral infection inhibiting compound is 1,000 or more, the heat aging resistance of the viral infection inhibitor can be improved. When the viral infection inhibiting compound is contained in a substrate, the viral infection inhibiting effect can be more effectively exerted without impairing the appearance of the substrate, and the number of adsorption points with viruses per molecule of the viral infection inhibiting compound increases, strengthening the interaction between the viral infection inhibiting compound and viruses and improving the viral infection inhibiting effect of the viral infection inhibitor.

[0041] The weight-average molecular weight of the polymer contained in the viral infection-inhibiting compound is preferably 1,000,000 or less, more preferably 900,000 or less, more preferably 800,000 or less, and more preferably 500,000 or less. When the weight-average molecular weight of the viral infection-inhibiting compound is 1,000,000 or less, the heat aging resistance of the viral infection inhibitor can be improved. When the viral infection inhibitor is contained in a substrate, the viral infection-inhibiting effect can be more effectively exerted without impairing the appearance of the substrate.

[0042] In the present invention, the weight average molecular weight of the polymer is a value measured by GPC (gel permeation chromatography) and converted into polystyrene.

[0043] For example, the measurement can be performed using the following measurement device and under the following measurement conditions. Gel permeation chromatograph: Waters, product name "2690 Separations Model" Column: Showa Denko Co., Ltd., product name "GPC KF-806L" Detector: differential refractometer Sample flow rate: 1 mL / min Column temperature: 40℃ Eluent: THF

[0044] The viral infection-inhibiting compound is preferably formed into particles. The D90 particle size of the viral infection-inhibiting compound is preferably 2 μm or more, more preferably 2.5 μm or more, more preferably 3 μm or more, and more preferably 3.5 μm or more. The D90 particle size of the viral infection-inhibiting compound is preferably 25 μm or less, more preferably 22 μm or less, more preferably 20 μm or less, more preferably 18 μm or less, more preferably 16 μm or less, more preferably 14 μm or less, and more preferably 12 μm or less. When the D90 particle size is 2 μm or more, the surface area of ​​the entire viral infection-inhibiting compound is reduced, the agglomeration of the viral infection inhibitor is reduced, and the viral infection-inhibiting compound and the virus are in a form that facilitates interaction, thereby improving the viral infection-inhibiting effect of the viral infection inhibitor. When the D90 particle size is 25 μm or less, aggregation of the virus infection inhibitor is reduced and the surface area is increased, facilitating contact with the virus, thereby improving the virus infection inhibitory effect of the virus infection inhibitor compound, and also reducing aggregation of the virus infection inhibitor and reducing the loss of transparency of the virus infection inhibitor product in a high-temperature environment.

[0045] By adjusting the D90 particle size of the viral infection-inhibiting compound to the above-mentioned range and adjusting the particle size of large particles in the viral infection-inhibiting compound to a predetermined range, the inclusion of coarse particles in the viral infection-inhibiting compound is reduced. The viral infection-inhibiting compound has a sulfo group salt on its surface, and by adjusting the particle size of the viral infection-inhibiting compound to the above-mentioned range, the amount of sulfo group salt present on the surface of the viral infection-inhibiting compound is adjusted, imparting an excellent viral infection-inhibiting effect to the viral infection-inhibiting agent and improving the heat aging resistance of the viral infection-inhibiting agent.

[0046] The D50 particle size of the viral infection-inhibiting compound is preferably 0.5 μm or more, more preferably 1 μm or more, more preferably 1.5 μm or more, and more preferably 2.0 μm or more. The D50 particle size of the viral infection-inhibiting compound is preferably 25 μm or less, more preferably 20 μm or less, more preferably 14 μm or less, more preferably 12 μm or less, and more preferably 11 μm or less.

[0047] By setting the D50 particle size and D90 particle size of the viral infection-inhibiting compound within the above-mentioned ranges, the inclusion of coarse particles having particle sizes significantly different from the D50 particle size in the viral infection-inhibiting compound can be reduced, and the particle size of the viral infection-inhibiting compound can be made more appropriate.

[0048] Furthermore, by adjusting the particle size of the viral infection-inhibiting compound to a more appropriate range, the amount of sulfo group salt present on the surface of the viral infection-inhibiting compound can be more appropriately adjusted, more effectively imparting an excellent viral infection-inhibiting effect to the viral infection-inhibiting agent, while also imparting excellent dispersibility to the viral infection-inhibiting agent and reducing the loss of transparency of the viral infection-inhibiting product in high-temperature environments.

[0049] The D90 particle size and D50 particle size of a viral infection-inhibiting compound refer to the particle sizes (90% cumulative particle size and 50% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in the volume-based particle size distribution measured by laser scattering method is 90% and 50%, respectively. When a viral infection-inhibiting compound contains multiple types of viral infection-inhibiting compounds, the D90 particle size and D50 particle size of the viral infection-inhibiting compound are values ​​measured based on the entire viral infection-inhibiting compound.

[0050] [Organic acid] The viral infection inhibitor contains an organic acid as an active ingredient. The organic acid is a compound different from the viral infection inhibitor compound containing a salt of a sulfo group. The organic acid does not contain a salt of a sulfo group in the molecule. The organic acid excludes organic acids having a salt of a sulfo group. By combining the specified viral infection inhibitor compound and the organic acid, the viral infection inhibitor improves the heat aging resistance of the viral infection inhibitor product containing the viral infection inhibitor, and the color of the viral infection inhibitor product is not impaired even when placed in a high-temperature environment. When the viral infection inhibitor product is transparent, it can stably maintain its transparency for a long period of time even in a high-temperature environment.

[0051] An organic acid is an acidic compound containing at least one carbon atom (preferably two or more) and a carbon-hydrogen bond (C—H bond) in the molecule. The organic acid preferably has at least one acidic functional group selected from the group consisting of a carboxyl group (—COOH), a sulfo group (—SOH), and a phosphonic acid group [—P(═O)(OH)], and more preferably has a carboxyl group. The organic acid is not particularly limited, and examples thereof include mellitic acid, aconitic acid, citric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, fumaric acid, maleic acid, itaconic acid, citraconic acid, mesaconic acid, phthalic acid, isophthalic acid, terephthalic acid, methylenedisalicylic acid, cis-Δ4-tetrahydrophthalic acid, gluconic acid, mucic acid, 3,3'-thiodipropionic acid, 2,2'-thiodiglycolic acid, 3,3'-dithiodipropionic acid, 2,2'-dithiodiglycolic acid, 2,2'-dithiosalicylic acid, 4,4'-dithiodibutyric acid, 3-(dodecylthio)propionic acid, picolinic acid, formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, and pelargonic acid. Examples of organic acids include capric acid, crotonic acid, glycolic acid, lactic acid, malic acid, tartaric acid, quinic acid, salicylic acid, benzoic acid, vanillic acid, gallic acid, mandelic acid, phloretic acid, coumaric acid, caffeic acid, ferulic acid, sinapic acid, 4-aminobenzoic acid, triglycolaminic acid, diethylenetriaminepentaacetic acid, carboxymethylcellulose, carboxymethylated chitosan, carboxymethylated chitin, carboxymethyldextran, carboxymethyl-β-cyclodextrin, carboxysucrose, pectin, xanthan gum, alginic acid, hyaluronic acid, fulvic acid, humic acid, uronic acid, arabinonic acid, fructuronic acid, tagaturonic acid, glucuronic acid, iduronic acid, galacturonic acid, mannuronic acid, and guluronic acid. The organic acids may be used alone or in combination of two or more.

[0052] In organic acids, the sum of the Sanderson electronegativities normalized by carbon is 28 or less. When the sum of the Sanderson electronegativities normalized by carbon is 28 or less, the interaction between the atoms of the organic acid is increased and the structure of the organic acid molecule is stabilized, which inhibits deterioration of the molecular structure and improves the heat aging resistance of the virus infection inhibitor.

[0053] For organic acids, the sum of Sanderson's electronegativities normalized by carbon is a value measured as follows. Sanderson's electronegativities are known to be, for example, 2.746 for carbon, 2.592 for hydrogen, and 3.654 for oxygen. The values ​​of these atoms are divided by the carbon value of 2.746 to obtain normalized values, such as 1.00 for carbon, 0.944 for hydrogen, and 1.33 for oxygen, and these values ​​are taken as the carbon-normalized Sanderson electronegativities. The sum of the carbon-normalized Sanderson electronegativities of each atom in the organic acid is calculated, and this value is taken as the sum of the carbon-normalized Sanderson electronegativities of the organic acid.

[0054] In the organic acid, the sum of Sanderson's electronegativities normalized by carbon is 28 or less, preferably 27 or less, more preferably 25 or less, and more preferably 22 or less. In the organic acid, the sum of Sanderson's electronegativities normalized by carbon is preferably 5 or more, more preferably 7 or more, and more preferably 10 or more. When the sum of Sanderson's electronegativities normalized by carbon is 28 or less, the heat aging resistance of the virus infection inhibitor is improved. When the sum of Sanderson's electronegativities normalized by carbon is 5 or more, the virus infection inhibitory effect of the virus infection inhibitor is improved.

[0055] In organic acids, the sum of Sanderson's electronegativity normalized by carbon can be decreased by decreasing the number of carbon atoms, the number of carbon-carbon double bonds, and the number of functional groups such as carboxylic acids and benzene rings in the molecule.In organic acids, the sum of Sanderson's electronegativity normalized by carbon can be increased by increasing the number of carbon atoms, the number of carbon-carbon double bonds, and the number of functional groups such as carboxylic acids and benzene rings in the molecule.

[0056] In the organic acid, the sum of the first ionization tendencies normalized by carbon is not more than 30. When the sum of the first ionization tendencies is not more than 30, the reactivity of the organic acid with oxygen molecules is reduced, and oxidative deterioration of the organic acid molecules is less likely to occur, thereby improving heat aging resistance.

[0057] The sum of the first ionization tendencies normalized by carbon of an organic acid refers to a value measured in the following manner. Known first ionization tendencies are, for example, carbon: 1086.5, hydrogen: 1312, and oxygen: 1313.9. The values ​​of these atoms are normalized by dividing them by the carbon value of 1086.5, resulting in values ​​of carbon: 1.00, hydrogen: 1.208, and oxygen: 1.209, respectively, and these values ​​are taken as the first ionization tendencies normalized by carbon. The sum of the values ​​of the first ionization tendencies normalized by carbon for each atom in the organic acid is calculated, and this value is taken as the sum of the first ionization tendencies normalized by carbon for the organic acid.

[0058] In the organic acid, the sum of the first ionization tendencies normalized by carbon is 30 or less, preferably 27 or less, more preferably 25 or less, and more preferably 22 or less. In the organic acid, the sum of the first ionization tendencies normalized by carbon is preferably 5 or more, more preferably 7 or more, and more preferably 10 or more. When the sum of the first ionization tendencies normalized by carbon is 30 or less, an energetically unstable ionic state is less likely to occur and the organic acid molecule is stabilized, thereby suppressing deterioration of the molecular structure and improving the heat aging resistance of the virus infection inhibitor. When the sum of the first ionization tendencies normalized by carbon is 5 or more, the virus infection inhibitory effect of the virus infection inhibitor is improved.

[0059] By limiting the sum of the carbon-normalized Sanderson electronegativities and the sum of the carbon-normalized first ionization tendencies of the organic acid to within a predetermined range, the interaction between the atoms of the organic acid is increased while the reactivity of the organic acid with oxygen molecules is reduced, thereby improving the heat aging resistance of the virus infection inhibitor.

[0060] In organic acids, the sum of first ionization tendencies can be decreased by decreasing the number of carbon atoms, the number of carbon-carbon double bonds, or the number of functional groups such as carboxylic acids and benzene rings in the molecule. In organic acids, the sum of first ionization tendencies can be increased by increasing the number of carbon atoms, the number of carbon-carbon double bonds, or the number of functional groups such as carboxylic acids and benzene rings in the molecule.

[0061] The number of sp3 carbons in the organic acid is preferably 10 or less, more preferably 8 or less, and even more preferably 6 or less. The organic acid does not have to have sp3 carbons, but the number of sp3 carbons in the organic acid is preferably 1 or more, more preferably 2 or more. When the number of sp3 carbons in the organic acid is 10 or less, the crystallinity of the organic acid molecule is improved, the organic acid is less susceptible to deterioration, and the heat aging resistance of the viral infection inhibitor is improved. When the organic acid has no sp3 carbons or the number of sp3 carbons in the organic acid is 1 or more, the unsaturated bonds of the organic acid are reduced, oxidative deterioration of the organic acid is reduced, and the heat aging resistance of the viral infection inhibitor is improved.

[0062] An sp3 carbon is a carbon that forms single bonds with four other atoms, excluding carbons that are bonded to other atoms by double and triple bonds.

[0063] In the viral infection inhibitor, the total content of organic acids having a sum of carbon-normalized Sanderson electronegativities greater than 28 and organic acids having a sum of carbon-normalized first ionization tendencies greater than 30 may be contained within a range that does not inhibit the action of the viral infection inhibitor, and is preferably 5 parts by mass or less, more preferably 3 parts by mass or less, more preferably 1 part by mass or less, and more preferably 0 parts by mass per 100 parts by mass of the viral infection inhibitor compound.

[0064] The pKa1 of the organic acid at 25°C is preferably 5.5 or less, more preferably 4.6 or less, and more preferably 3.6 or less. The pKa1 of the acidic compound at 25°C is preferably 1.0 or more, more preferably 2.0 or more, and even more preferably 2.8 or more. When the pKa1 of the organic acid at 25°C is 5.5 or less, adsorption of viruses to the virus infection inhibitor is promoted, and the virus infection inhibitory effect of the virus infection inhibitory product is improved. When the pKa1 of the organic acid at 25°C is 1.0 or more, deterioration of the virus infection inhibitory product by the organic acid is suppressed, and the virus infection inhibitory product can be imparted with excellent heat aging resistance, and the transparency and color of the virus infection inhibitory product are not impaired even when placed in a high-temperature environment.

[0065] Here, in the present invention, the electrolyte HA is A - and H + When an acid dissociates into ions and the ionization equilibrium is obtained as shown in equation (1), the acid dissociation constant Ka is defined by equation (2), and pKa is defined as the common logarithm (3) of the reciprocal of the acid dissociation constant Ka.

[0066] When the organic acid is a polyvalent acid, the polyvalent acid undergoes ionization in multiple stages, and pKa1 refers to the pKa calculated based on the ionization constant of the first stage.

[0067]

number

[0068] The pKa1 of an organic acid at 25°C is a value measured by titration. Specifically, the pKa1 can be determined by titrating the organic acid with sodium hydroxide at 25°C and measuring the pH at 25°C at the half-equivalent point (the point at which half the amount required for complete neutralization has been added dropwise).

[0069] The pH of a 0.5% by mass aqueous solution of an organic acid at 25°C is preferably 4.5 or less, more preferably 4.0 or less, and even more preferably 3.5 or less. When the pH of a 0.5% by mass aqueous solution of an organic acid at 25°C is 4.5 or less, the interaction between the viral infection inhibitors is strengthened, thereby imparting excellent heat aging resistance to the viral infection-inhibiting product. This further reduces loss of color, such as transparency, of the viral infection-inhibiting product even when placed in a high-temperature environment. The pH of a 0.5% by mass aqueous solution of an organic acid at 25°C refers to the pH value at 25°C of a liquid (mixed liquid) obtained by adding 0.5 g of organic acid to 99.5 g of purified water and uniformly mixing the liquid. If an organic acid precipitates in the mixed liquid, the mixed liquid should be a saturated solution of all of the precipitated organic acids. If the organic acid is a mixture, the pH of the organic acid refers to the pH of the entire organic acid.

[0070] The content of the organic acid in the viral infection inhibitor is preferably 40 parts by mass or more, more preferably 100 parts by mass or more, and more preferably 500 parts by mass or more, per 100 parts by mass of the viral infection inhibitory compound. The content of the organic acid in the viral infection inhibitor is preferably 6,000 parts by mass or less, more preferably 5,000 parts by mass or less, and more preferably 4,000 parts by mass or less, per 100 parts by mass of the viral infection inhibitory compound. When the content of the organic acid is 40 parts by mass or more, the organic acid promotes adsorption of the viral infection inhibitor to viruses, thereby providing even more excellent viral infection inhibitory effects. When the content of the organic acid is 6,000 parts by mass or less, it is possible to reduce deterioration of the viral infection inhibitory product due to the organic acid, while providing the viral infection inhibitor with even more excellent heat aging resistance, and the transparency and color of the viral infection inhibitory product are not impaired even when placed in a high-temperature environment.

[0071] The organic acid is preferably supported on the surface of the base particle. By supporting the organic acid on the surface of the base particle, the heat aging resistance of the virus infection inhibitor can be improved, aggregation of the virus infection inhibitor can be reduced, the virus infection inhibitor can be uniformly contained in the base material, and a uniform and excellent virus infection inhibitory effect can be imparted to the base material. The base particle to which the organic acid is attached on the surface is not particularly limited as long as it does not inhibit the heat aging resistance of the virus infection inhibitor. The particles include resin particles and inorganic particles. The particles may be used alone or in combination of two or more types.

[0072] The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include silica, zeolite, diatomaceous earth, kaolin, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, aluminum hydroxide, magnesium hydroxide, titanium oxide, and talc.

[0073] Examples of synthetic resins constituting the resin particles include styrene-based resins, acrylic-based resins, urethane-based resins, vinyl chloride-based resins, ABS resins, and synthetic rubbers such as styrene-butadiene rubber (SBR) and nitrile-butadiene rubber (NBR). Of these, styrene-based resins are preferred, and polystyrene is more preferred.

[0074] The styrene-based resin is not particularly limited, and examples thereof include homopolymers or copolymers containing, as monomer units, styrene-based monomers such as styrene, methylstyrene, ethylstyrene, i-propylstyrene, dimethylstyrene, chlorostyrene, and bromostyrene, and copolymers containing, as monomer units, a styrene-based monomer and one or more vinyl monomers copolymerizable with the styrene-based monomer.

[0075] Examples of vinyl monomers copolymerizable with styrene-based monomers include acrylic monomers such as acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic acid esters (methyl acrylate, ethyl acrylate, butyl acrylate, etc.), methacrylic acid esters (methyl methacrylate, ethyl methacrylate, butyl methacrylate, etc.), maleic anhydride, and acrylamide.

[0076] The acrylic resin is not particularly limited, and examples thereof include homopolymers or copolymers containing, as monomer units, acrylic monomers such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, and pentyl (meth)acrylate, and copolymers containing, as monomer units, an acrylic monomer and one or more vinyl monomers copolymerizable with the acrylic monomer. Note that (meth)acrylate means acrylate or methacrylate.

[0077] Examples of vinyl monomers copolymerizable with acrylic monomers include acrylonitrile, methacrylonitrile, maleic anhydride, and acrylamide.

[0078] The organic acid has hydrophobic properties in the organic chain portion (hydrophobic portion) represented by the carbon-hydrogen bond portion. The organic chain portion of the organic acid has excellent affinity with the resin particles, while the acidic functional group portion (e.g., carboxyl group) which has lower affinity with the resin particles than the organic chain portion tends to face outward, improving the interaction with the virus infection inhibitor compound and improving the heat aging resistance of the virus infection inhibitor.

[0079] The synthetic resin constituting the resin particles preferably contains an aromatic ring, which attracts the hydrophobic moiety of the organic acid attached to the surface of the resin particles and orients the acidic functional group (e.g., -COOH) of the organic acid outward, thereby enabling the virus infection inhibitor to more effectively exhibit heat aging resistance.

[0080] The aromatic ring may be a monocyclic aromatic ring, or may be a fused monocyclic aromatic ring (fused aromatic ring). The aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, biphenyl, and phenoxyphenyl. The aromatic ring has one or more hydrogen atoms removed from either the aromatic ring or the fused aromatic ring, and is bonded to other atoms via a covalent bond.

[0081] The D50 particle size of the base particles is preferably 0.1 μm or more, more preferably 0.2 μm or more, more preferably 1 μm or more, and more preferably 2 μm or more. The D50 particle size of the base particles is preferably 200 μm or less, more preferably 100 μm or less, more preferably 80 μm or less, more preferably 60 μm or less, more preferably 40 μm or less, more preferably 20 μm or less, and more preferably 10 μm or less.

[0082] When the D50 particle size of the base particles is 0.1 μm or more, the organic acid can be dispersed and supported on the surface of the base particles, improving the interaction between the viral infection inhibitory compound and the organic acid and improving the heat aging resistance of the viral infection inhibitor.

[0083] When the D50 particle size of the base particles is 200 μm or less, the occurrence of abnormal appearance such as bumps on the surface of a viral infection-inhibiting product containing a viral infection inhibitor can be reduced, and a viral infection-inhibiting product with excellent appearance can be obtained.

[0084] The D50 particle size of a base particle refers to the particle size (50% cumulative particle size) at which the cumulative frequency (cumulative from particles with small particle sizes) in the volume-based particle size distribution measured by laser scattering method is 50%. When the base particle contains multiple types of base particles, the D50 particle size of the base particle is the value measured based on the entire base particle.

[0085] The amount of organic acid attached to the base particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more, per 100 parts by mass of base particles. The amount of organic acid attached to the base particles is preferably 600 parts by mass or less, more preferably 500 parts by mass or less, more preferably 400 parts by mass or less, and more preferably 300 parts by mass or less, per 100 parts by mass of base particles. When the amount of organic acid attached is 1 part by mass or more, the organic acid can be uniformly attached to the surface of the base particles, and the heat aging resistance of the virus infection inhibitor can be more effectively exhibited. When the amount of organic acid attached is 600 parts by mass or less, the organic acids do not bond to each other, and the organic acid is efficiently arranged on the surface of the base particles, improving the heat aging resistance of the virus infection inhibitor.

[0086] The method for supporting the organic acid on the surface of the base particle is not particularly limited, and may be, for example, by relying on the adhesive strength of the organic acid, or by using a binder resin to adhere the organic acid to the surface of the base particle. However, since this improves the heat aging resistance of the virus infection inhibitor, it is preferable that the organic acid adhere to the surface of the base particle by the adhesive strength of the organic acid itself.

[0087] [Virus infection inhibitor] The virus infection inhibitor can be produced by uniformly mixing the virus infection inhibitor compound and the organic acid in a conventional manner.

[0088] In the viral infection inhibitor, the total amount of the viral infection inhibitory compound and organic acid is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0089] The viral infection inhibitor has an inhibitory effect on various viruses due to the action of the viral infection inhibitor compound, and exhibits excellent viral infection inhibitory effect on both enveloped and non-enveloped viruses.

[0090] Examples of enveloped viruses include influenza viruses (e.g., influenza A, B, etc.), rubella viruses, Ebola viruses, coronaviruses (e.g., SARS virus, novel coronavirus (SARS-CoV-2)), measles viruses, varicella-zoster viruses, herpes simplex viruses, mumps viruses, arboviruses, respiratory syncytial viruses, hepatitis viruses (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever viruses, AIDS viruses, rabies viruses, hantaviruses, dengue viruses, Nipah viruses, and lyssaviruses.

[0091] Examples of non-enveloped viruses include feline calicivirus, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, and rhinovirus.

[0092] The virus infection inhibitor is used by being contained in a base material to which it is desired to impart a virus infection inhibitory effect, and the base material containing the virus infection inhibitor exhibits a virus infection inhibitory effect as a virus infection inhibitory product.

[0093] Furthermore, because the virus infection inhibitor has excellent heat aging resistance, a substrate containing the virus infection inhibitor can maintain its original appearance for a long period of time, even in a high-temperature environment, without discoloration due to the virus infection inhibitor. In particular, when the substrate is transparent, a virus infection-inhibiting product obtained by incorporating the virus infection inhibitor into the substrate can maintain excellent transparency for a long period of time, even in a high-temperature environment.

[0094] The substrate to be loaded with the virus infection inhibitor is not particularly limited as long as it can contain the virus infection inhibitor, and examples include synthetic resin molded products such as films, paints, wallpaper, decorative sheets, flooring materials, textile products (woven fabrics, nonwoven fabrics, knitted fabrics), interior and interior materials for vehicles (for example, cars, airplanes, ships, etc.) (seats, child seats, and the foams that make up these), kitchenware, baby products, and building interior materials.

[0095] The synthetic resin constituting the synthetic resin molded article is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyethylene, polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyethersulfone, polyarylate, polyether ether ketone, thermoplastic polyimide, polyamideimide, etc.), thermosetting resins (e.g., phenolic resin, epoxy resin, melamine resin, urea resin, unsaturated polyester resin, alkyd resin, silicone resin, polyurethane, thermosetting polyimide, etc.). The synthetic resins may be used alone or in combination of two or more.

[0096] The virus infection inhibitor may be used by kneading it into a synthetic resin. A method for kneading the virus infection inhibitor into a synthetic resin involves mixing the virus infection inhibitor with a synthetic resin raw material to prepare a resin composition, and using this resin composition to obtain a virus infection-inhibiting product in a desired shape as a molded article by a general-purpose synthetic resin molding method. Examples of general-purpose synthetic resin molding methods include extrusion molding, injection molding, and blow molding. A synthetic resin and the virus infection inhibitor may be included in a synthetic resin molding masterbatch, which may be mixed with the synthetic resin raw material, and the virus infection-inhibiting product may be produced as a molded article by a general-purpose synthetic resin molding method.

[0097] As the paint, conventionally known paints are used, for example, oil-based paints (e.g., mixed paints, oil varnishes, etc.), cellulose paints, synthetic resin paints, etc. The paint also includes photocurable paints that polymerize upon irradiation with radiation such as ultraviolet light to produce a binder component.

[0098] Because the virus infection inhibitor has excellent heat aging resistance, the coating film produced from a paint containing the virus infection inhibitor does not discolor over a long period of time. Therefore, an article having a coating film formed on its surface can maintain its appearance over a long period of time. In particular, if the coating film is transparent, the article having the coating film formed thereon can maintain its appearance over a long period of time.

[0099] The paint may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, antioxidants, thickeners, and surfactants, as long as the additives do not impair the paint's physical properties. Examples of methods for incorporating the virus infection inhibitor into the paint include a method in which the virus infection inhibitor and the paint are supplied to a dispersing device and mixed uniformly. Examples of dispersing devices include a high-speed mill, a ball mill, and a sand mill.

[0100] The building interior materials are not particularly limited, and examples thereof include flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, wax, and the like.

[0101] The vehicle interior goods and materials are not particularly limited, and examples thereof include seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trim, instrument panels, consoles, glove boxes, handrails, and the like. [Example]

[0102] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0103] The following compounds were prepared as viral infection-inhibiting compounds and organic acids. When the viral infection-inhibiting compound was a polymer, the weight-average molecular weight was shown in the "Mw" column of Table 1.

[0104] [Viral infection inhibitor compound] Sodium polystyrene sulfonate (Na polystyrene sulfonate) Sodium α-olefin sulfonate (Na α-olefin sulfonate) Sodium alkyldiphenyl ether disulfonate (Na alkyldiphenyl ether disulfonate) Sodium dodecylbenzenesulfonate (Na dodecylbenzenesulfonate)

[0105] [Organic acid] The compounds used were those listed in the "Type" column of organic acid in Table 1. For the organic acids, the "sum of Sanderson electronegativity normalized by carbon," "sum of first ionization tendency normalized by carbon," "number of sp3 carbons," "pKa1 at 25°C," and "pH of a 0.5% by mass aqueous solution at 25°C" are listed in the "Electronegativity," "First ionization tendency," "Number of sp3 carbons," "pKa1," and "pH" columns in Table 1, respectively.

[0106] [Base particle (particle)] Styrene resin particles (D50 particle size: 4 μm) Acrylic resin particles (D50 particle size: 5 μm) Silica particles (D50 particle size: 4.5 μm)

[0107] [Preparation of particles containing compounds that inhibit viral infection] The freeze-dried virus infection-inhibiting compound powder was coarsely pulverized using a roll press (Seishin Enterprise Co., Ltd., product name "150 type") at a rotation speed of 25 rpm and a pressure of 25 tons, and then pulverized using a jet mill (Nisshin Engineering, product name "SJ-500") at a feed rate of 1 kg / h and a compressed air pressure of 0.75 MPa to obtain particles of the virus infection-inhibiting compound. The D50 and D90 particle sizes of the obtained particles of the virus infection-inhibiting compound are shown in Table 1. Note that sodium alkyldiphenyletherdisulfonate could not be pulverized because it is liquid at room temperature.

[0108] [Preparation of malic acid supported on styrene resin particles (styrene resin particle-supported malic acid)] Water was prepared in an amount 7 times the total mass of the malic acid particles and base particles (styrene resin particles). 10 parts by mass of the malic acid particles and 30 parts by mass of the styrene resin particles were added to the water and mixed uniformly to prepare a dispersion.

[0109] Next, the dispersion was powdered using a spray dryer at an atomizer rotation speed of 20,000 rpm, and the entire amount of malic acid particles was attached (supported) to the surfaces of the styrene resin particles.Then, using a jet mill (manufactured by Nisshin Engineering Inc., product name "SJ-500"), the particles were pulverized under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa, to obtain styrene resin particles with malic acid particles supported (attached) on their surfaces.

[0110] [Preparation of Malic Acid Supported on Acrylic Resin Particles (Malic Acid Supported on Acrylic Resin Particles)] Water was prepared in an amount 7 times the total mass of the malic acid particles and base particles (acrylic resin particles). 10 parts by mass of the malic acid particles and 30 parts by mass of the acrylic resin particles were added to the water and mixed uniformly to prepare a dispersion.

[0111] Next, the dispersion liquid was powdered using a spray dryer at an atomizer rotation speed of 20,000 rpm, and the entire amount of malic acid particles was attached (supported) to the surfaces of the acrylic resin particles. After that, the resulting particles were pulverized using a jet mill (manufactured by Nisshin Engineering Inc., trade name "SJ-500") under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa, thereby obtaining acrylic resin particles with malic acid particles supported (attached) on their surfaces.

[0112] [Preparation of malic acid supported on silica particles (silica particle-supported malic acid)] Water was prepared in an amount 7 times the total mass of the malic acid particles and base particles (silica particles). 10 parts by mass of the malic acid particles and 30 parts by mass of the silica particles were added to the water and mixed uniformly to prepare a dispersion.

[0113] Next, the dispersion was powdered using a spray dryer at an atomizer rotation speed of 20,000 rpm, and the entire amount of malic acid particles was attached (supported) to the surface of the silica particles.Then, using a jet mill (manufactured by Nisshin Engineering Inc., product name "SJ-500"), the mixture was pulverized under operating conditions of a raw material supply rate of 1 kg / h and a compressed air pressure of 0.75 MPa, to obtain silica particles with malic acid particles supported (attached) on their surfaces.

[0114] (Example 1 21 , Comparative Examples 1 to 6, Reference Example 1 ) The viral infection inhibitors were prepared by mixing the viral infection inhibitor compounds and organic acids listed in the "Type" column in Table 1 in the amounts shown in the "Content" column in Table 1.

[0115] A coating composition was prepared by mixing 5 parts by mass of the virus infection inhibitor with 95 parts by mass of an ultraviolet-curable acrylic paint (manufactured by Coattec Co., Ltd. under the trade name "AI-N2"), and the coating composition was applied to a polyethylene film using a wire bar coater #8 to form a coating layer with a thickness of 18 μm.

[0116] Using a UV conveyor device (Eye Graphics "ECS301G1"), ultraviolet light with a wavelength of 365 nm was applied to the coating layer at 25°C with an integrated light intensity of 500 mJ / cm. 2 The ultraviolet-curable acrylic paint was cured by irradiating it so as to form a coating film with a thickness of 18 μm.

[0117] The resulting coating film was subjected to an antiviral test and heat aging resistance measurement in the following manner, and the results are shown in Table 1.

[0118] (Antiviral test) A test piece was prepared by cutting out a flat square piece with each side measuring 5.0 cm from the coating film.

[0119] The surface of the coating film on the obtained test piece was soaked in 1 mL of water with a flat square nonwoven fabric (manufactured by Nippon Paper Crecia Co., Ltd., product name "Kimwipe S-200") with each side measuring 10 cm, and the coating film surface was wiped with the nonwoven fabric by moving it back and forth 10 times to obtain a test coating film.

[0120] The obtained test coating film was subjected to antiviral tests against influenza virus and feline calicivirus in accordance with ISO 21702. The virus infectivity of the test coating film was calculated by the plaque method for the virus suspension after the reaction.

[0121] A blank coating was prepared in the same manner as above, except that no virus infection inhibitor was added, and the virus infectivity (common logarithm) (PFU / cm) was calculated based on this blank coating in the same manner as above. 2 The virus infectivity titer (common logarithm) of the blank coating was 6.5 PFU / cm 2 It was.

[0122] The antiviral activity value was calculated by subtracting the viral infectivity of the test coating from the viral infectivity of the blank coating.

[0123] (Heat aging resistance) The test coating film was treated at 120°C for 1000 hours. The haze of the test coating film before and after treatment was evaluated in accordance with JIS K7361. Haze (%) was measured using a haze meter ("HM-150" manufactured by Murakami Color Research Laboratory Co., Ltd.) in an environment of room temperature 25°C and relative humidity 40%. Delta haze was calculated by subtracting the haze value before treatment from the haze value after treatment. The smaller the delta haze, the better the heat aging resistance. The smaller the delta haze, the better the heat aging resistance.

[0124] [Table 1] [Industrial Applicability]

[0125] The virus infection inhibitor of the present invention allows the production of a virus infection-inhibiting product that exhibits excellent appearance for a long period of time without any significant loss in transparency even when placed in a high-temperature environment.

[0126] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims priority to Japanese Patent Application No. 2022-128508, filed on August 10, 2022, the disclosure of which is incorporated herein by reference in its entirety.

Claims

1. a viral infection-inhibiting compound having a salt of a sulfo group; an organic acid having a carbon-normalized sum of Sanderson electronegativities of 28 or less and a carbon-normalized sum of first ionization tendencies of 30 or less, The organic acid is a compound that does not contain a salt of a sulfo group in the molecule and has a carboxy group (—COOH), The virus infection inhibitor is characterized in that the virus infection inhibitor compound is in a particulate form and has a D90 particle size of 2 μm or more and 25 μm or less.

2. 2. The virus infection inhibitor according to claim 1, wherein the organic acid has 10 or less sp3 carbon atoms.

3. 3. The virus infection inhibitor according to claim 1, wherein the organic acid has a pKa of 5.5 or less at 25°C.

4. 3. The virus infection inhibitor according to claim 1, wherein the pH of a 0.5% by mass aqueous solution of the organic acid at 25°C is 4.5 or less.

5. 3. The virus infection inhibitor according to claim 1, wherein the organic acid is supported on the surface of a base particle.

6. 6. The virus infection inhibitor according to claim 5, wherein the base particles are acrylic resin particles, styrene resin particles, or inorganic particles.

7. the D90 particle size of the viral infection-inhibiting compound is 2 μm or more and 22 μm or less; the organic acid has a carbon-normalized sum of first ionization tendencies of 22 or less; 2. The virus infection inhibitor according to claim 1, wherein the virus infection inhibitor contains 40 to 600 parts by mass of the organic acid per 100 parts by mass of the virus infection inhibitor compound having a salt of a sulfo group.

8. A resin composition comprising a synthetic resin and the virus infection inhibitor according to claim 1 or 2.

9. 9. The resin composition according to claim 8, which is used as a masterbatch for synthetic resin molding.

10. A virus infection-inhibiting product comprising a substrate and the virus infection-inhibiting agent according to claim 1 or 2 contained in the substrate.

Images